Thermo Fisher Scientific and UC Davis Launch Center of Excellence in Clinical Metabolomics

- Thermo Fisher Scientific, (NYSE: TMO) the world leader in serving science, and the University of California, Davis (UC Davis) West Coast Metabolomics Center today announced The Center of Excellence in Clinical Metabolomics, a research collaboration to provide the metabolomics community with innovations, best practices and standard operating procedures to support the rapid scale-up of large cohort studies and clinical research.

A scientist operates a Thermo Scientific Vanquish UHPLC with Q-Exactive HF-X mass spectrometer used in metabolomics research.

Metabolomics is an increasingly important field where researchers identify diagnostic biomarkers for disease, discover new drug targets, develop tools to predict drug response, and enable precision medicine overall. Advancements in this area can help ensure that patients receive more targeted medicines and increase the likelihood those therapies will achieve their intended outcomes.

The Center of Excellence in Clinical Metabolomics, based on the UC Davis Sacramento campus, will enable targeted and untargeted metabolic profiling for large-scale population-based cohorts across translational research and precision medicine. The Center will develop standardized processes for the research community, including end-to-end metabolic profiling workflows; optimized liquid chromatography-mass spectrometry (LC-MS) methods, protocols for analytical controls to monitor instrument performance; and training courses for metabolomics staff, scientists and core lab managers.

"The progress we've made in the areas of vaccines and therapy development during the pandemic would have been impossible without ongoing commitments to invest in and share new scientific techniques, and this underscores the importance of our collaboration with UC Davis," said Mark Stevenson , executive vice president and chief operating officer of Thermo Fisher. "The work we'll do here serves science by refining basic, but critical scientific techniques for metabolomics so they can quickly become clinically relevant."

As part of the collaboration, Thermo Fisher is providing its powerful Orbitrap technology . The Center will generate high-quality data using the latest generation of Orbitrap-based mass spectrometers in conjunction with the Thermo Scientific Vanquish Duo UHPLC system for increased throughput. This instrument combination will support the development of streamlined workflows for large-scale studies and translational research.

"We aim to provide advance training courses for early career community members as well as independent investigators and scientists, and this will be supported by state-of-the-art technology from Thermo Fisher ," said Oliver Fiehn , director, West Coast Metabolomics Center at the UC Davis Genome Center. "This collaboration will drive the creation of innovative analytical approaches for both untargeted and targeted applications providing the metabolomics community with advanced methodologies for their vital work."

For more information, please visit www.metabolomics.ucdavis.edu/clinical-metabolomics

About UC Davis West Coast Metabolomics Center
Since 2004, the UC Davis West Coast Metabolomics Center is an international leader in metabolomics research, service and education. The Center combines four metabolomic research laboratories with a large service core, training courses, seminars and workshops. We provide opportunities for research collaborations but also make general fee-based services available to biomedical, preclinical and clinical researchers, including industry investigators. We advance the state-of-the art in mass spectrometry-based metabolomics research, specifically in computational metabolomics. The Center hosts MassBank.us and a wide range of other tools and data repositories for freely available downloads. For more information, please visit www.metabolomics.ucdavis.edu

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion . Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com .

Media Contact Information:
Ron O'Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com

Investor Contact Information:
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com

Thermo Fisher Scientific logo (PRNewsfoto/Thermo Fisher Scientific)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/thermo-fisher-scientific-and-uc-davis-launch-center-of-excellence-in-clinical-metabolomics-301326475.html

SOURCE Thermo Fisher Scientific

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Medtronic chairman and CEO Geoff Martha to speak at Bernstein's Strategic Decisions Conference

Medtronic chairman and CEO Geoff Martha to speak at Bernstein's Strategic Decisions Conference

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it will participate in Bernstein's 41st Strategic Decisions Conference on Thursday, May 29, 2025 .

Geoff Martha , Medtronic chairman and chief executive officer, will make a formal presentation beginning at 11:00 a.m. EDT ( 10:00 a.m. CDT ). Immediately following the presentation, Martha will be joined by Thierry Piéton, Medtronic executive vice president and chief financial officer, to answer questions about the company.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase

Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase

Building momentum in key franchises including Pulsed Field Ablation, TAVR, Cardiac Rhythm Management, Diabetes, Spine, and Neuromodulation

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its fourth quarter (Q4) and fiscal year 2025 (FY25), which ended April 25, 2025 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Medtronic announces intent to separate Diabetes business

Medtronic announces intent to separate Diabetes business

Enables intense focus on highest margin growth drivers where Medtronic has leading core competencies

Leading, scaled, direct-to-consumer Diabetes business poised to become standalone company; only company with a complete ecosystem to address intensive insulin management

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

  • FDA Breakthrough Device Designation Awarded to AVIM Therapy
  • FDA IDE Approved for Virtue SAB U.S. Pivotal Trial for Launch

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced financial results for the first quarter ended March 31, 2025, and provided a business update highlighting continued regulatory momentum, disciplined operational execution, and a strengthening clinical development pipeline.

Q1 2025 Highlights:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Medtronic to announce financial results for its fourth quarter and full fiscal year 2025

Medtronic to announce financial results for its fourth quarter and full fiscal year 2025

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2025 on Wednesday, May 21, 2025 . A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at https:news.medtronic.com . The news release will include summary financial information for the company's fourth quarter and full fiscal year 2025, which ended on Friday, April 25, 2025 .

Medtronic will host a video webcast at 7:00 a.m. CDT on May 21, 2025 , to discuss results for its fourth quarter and full fiscal year 2025. The webcast can be accessed at https://investorrelations.medtronic.com .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
New survey: 1 in 3 women have not talked to their doctor about heart health, the #1 killer of women

New survey: 1 in 3 women have not talked to their doctor about heart health, the #1 killer of women

Star Jones , award winning television personality & women's heart health advocate,   helps kick off heart health conversations this Mother's Day with the Medtronic 'Letter to My Mother' campaign

A new Medtronic-sponsored survey of women ages 30-50 reveals a significant gap in awareness and discussion around heart health among women and their mother-figures. Despite cardiovascular disease being the #1 killer of women in the U.S. many women are still unaware of the risk and the importance of heart health.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×